Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease

Autor: Michael D, Kappelman, Sruthi, Adimadhyam, Laura, Hou, Audrey E, Wolfe, Samantha, Smith, Andrew L, Simon, Érick, Moyneur, Juliane S, Reynolds, Sengwee, Toh, Angela, Dobes, Lauren E, Parlett, Kevin, Haynes, Mano, Selvan, Qianli, Ma, Vinit, Nair, Jessica, Burris, Jennifer E, Dorand, Ghadeer K, Dawwas, James D, Lewis, Millie D, Long

Publikováno v: American Journal of Gastroenterology. 118:674-684

Many patients with Crohn's disease (CD) lose response or become intolerant to antitumor necrosis factor (TNF) therapy and subsequently switch out of class. We compared the effectiveness and safety of ustekinumab to vedolizumab in a large, geographica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce194440dd26ba70e0f92d7d97dc2928
https://doi.org/10.14309/ajg.0000000000002068

GFR Estimation Using a Panel of Filtration Markers in Shanghai and Beijing

Autor: John H. Eckfeldt, Lesley A. Inker, Andrew L. Simon, Yujing Pan, Danshu Xie, Luxia Zhang, Shiyuan Miao, Jingyuan Xie, Nan Chen, Hao Shi, Wei Min-ji, Andrew S. Levey, Wen Zhang, Amy B. Karger, Hong Ren, Aghogho Okparavero, Juhi Chaudhari, Weiming Wang, Zhun Sui, Li Zuo

Publikováno v: Kidney Medicine, Vol 2, Iss 2, Pp 172-180 (2020)
Kidney Medicine

Rationale & Objectives Estimated glomerular filtration rate (eGFR) using creatinine and cystatin C (eGFRcr-cys) may be less accurate compared to measured GFR (mGFR) in China than in North America, Europe, and Australia due to variation across regions

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9ac9e752b4e595a9725b9292039e9ef
http://www.sciencedirect.com/science/article/pii/S2590059520300066

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials

Autor: Jian Ying, Lesley A. Inker, Hiddo J.L. Heerspink, Christoph Wanner, Vlado Perkovic, Ron T. Gansevoort, Edward F. Vonesh, Jürgen Floege, Josef Coresh, Andrew L. Simon, Tom Greene, Hocine Tighiouart, Andrew S. Levey, Gerald J. Beck, Philip Kam-Tao Li

Publikováno v: Journal of the American Society of Nephrology, 30(9), 1735-1745. AMER SOC NEPHROLOGY
J Am Soc Nephrol

BACKGROUND: Surrogate end points are needed to assess whether treatments are effective in the early stages of CKD. GFR decline leads to kidney failure, but regulators have not approved using differences in the change in GFR from the beginning to the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe3b3aa8510152e65b76fd3fdf527620
https://research.rug.nl/en/publications/21b30851-d2e2-4d50-9bb7-ff19c92c5d73

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

Autor: Hiddo J L Heerspink, Tom Greene, Hocine Tighiouart, Ron T Gansevoort, Josef Coresh, Andrew L Simon, Tak Mao Chan, Fan Fan Hou, Julia B Lewis, Francesco Locatelli, Manuel Praga, Francesco Paolo Schena, Andrew S Levey, Lesley A Inker, Angel Sevillano, Anne-Lise Kamper, Arjan D. van Zuilen, Barry M. Brenner, Bart Maes, Benno U. Ihle, Brendan Barret, CB Leung, CC Szeto, Christina Fitzner, Christoph Wanner, Claudio Pozzi, Claudio Ponticelli Montagnino, Di Xie, Dick de Zeeuw, Edmund Lewis, Eduardo Verde, Eduardo Gutierrez, Enyu Imai, Fernando Caravaca, Fernando C. Fervenza, Fumiaki Kobayashi, Gabriella Moroni, Gavin J. Becker, Gerald J. Beck, Gerald B. Appel, Gershon Frisch, GG van Essen, Giuseppe Maschio, Giuseppe Remuzzi, Giuseppe Montogrino, Hans-Henrik Parving, Hiddo J.L. Heerspink, Hirofumi Makino, Imitiaz Jehan, Jack F.M. Wetzels, James Donadio, Jamie Dwyer, Jan van den Brand, John Kusek, John M. Lachin, Jose Luño, Julia B. Lewis, Jürgen Floege, Kaleab Z. Abebe, KM Chow, Lawrence G. Hunsicker, Lucia del Vecchio, Manno Carlo, Marian Goicoechea, Maximilian von Eynatten, Neil Poulter, Nish Chaturvedi, Patrizia Passerini, Paul E. de Jong, Peter J. Blankestijn, Philip Li, Piero Ruggenenti, Pietro Zucchelli, Priscilla S. Kincaid-Smith, Ralf-Dieter Hilgers, Raymond O. Estacio, Richard D. Rohde, Ritsuko Katafuchi, Robert D. Toto, Robert W. Schrier, Roger A. Rodby, Ronald D. Perrone, Sadayoshi Ito, Saulo Klahr, Simeone Andrulli, Svend Strandgaard, Thierry P. Hannedouche, Thomas Rauen, Ursula Verdalles, Vlado Perkovic, William Keane

Publikováno v: Lancet Diabetes & Endocrinology, 7, 128-139
Lancet Diabetes & Endocrinology, 7(2), 128-139. ELSEVIER SCIENCE INC
The Lancet Diabetes and Endocrinology, 7(2), 128. Elsevier BV
Lancet Diabetes & Endocrinology, 7, 2, pp. 128-139

Background Change in albuminuria has strong biological plausibility as a surrogate endpoint for progression of chronic kidney disease, but empirical evidence to support its validity is lacking. We aimed to determine the association between treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3713b31bfb274314279f02c21f27d8f8
http://hdl.handle.net/2066/202989

In Reply to 'How Valid Are GFR Estimation Results From the CKD-EPI Databases?'

Autor: Lesley A. Inker, Andrew S. Levey, Andrew L. Simon, Hocine Tighiouart

Publikováno v: American journal of kidney diseases : the official journal of the National Kidney Foundation. 71(3)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f9e7f6daa8ba96d5766e8b57ca4f33b
https://pubmed.ncbi.nlm.nih.gov/29287799